The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress

Michael Maes; Mazin Fadhil Altufaili; Amer Fadhil Alhaideri; Shatha Rouf Moustafa; Kristina Stoyanova; Mengqi Niu; Bo Zhou; Jing Li; Hussein Kadhem Al‐Hakeim

doi:10.2174/0115680266320808240709061445

Shared by

Michael Maes

University of Electronic Science and Technology of China

The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress

Article 2024 en

Authors

Michael Maes
University Of Electronic Science & Technology Of China
MA
Mazin Fadhil Altufaili
AA
Amer Fadhil Alhaideri

Abstract

1 min read

Chronic Methamphetamine (MA) usage is linked to oxidative and AGE (advanced glycation end products) - RAGE (receptors for AGEs) stress, changes in magnesium, calcium, and copper, increased psychotic symptoms, and neurocognitive deficits. Nevertheless, it is still unclear whether these biological pathways mediate the latter impairments.

Discussion(0)

No comments yet. Be the first to comment.

The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress

Abstract

Discussion(0)

Related publications

The general neurocognitive decline in patients with methamphetamine (MA) use and transient MA-induced psychosis is primarily determined by oxidative and AGE-RAGE stress.

Increased AGE–RAGE axis stress in methamphetamine abuse and methamphetamine‐induced psychosis: Associations with oxidative stress and increased atherogenicity

Increased AGE-RAGE axis stress in methamphetamine (MA) abuse and MA-induced psychosis: associations with oxidative stress and increased atherogenicity

In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life

In (deficit) schizophrenia, a general cognitive decline (G-CoDe) partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life

Related publications

Preprint2024
The general neurocognitive decline in patients with methamphetamine (MA) use and transient MA-induced psychosis is primarily determined by oxidative and AGE-RAGE stress.
Preprint2024

Article2023
Increased AGE–RAGE axis stress in methamphetamine abuse and methamphetamine‐induced psychosis: Associations with oxidative stress and increased atherogenicity
Article2023

Preprint2023
Increased AGE-RAGE axis stress in methamphetamine (MA) abuse and MA-induced psychosis: associations with oxidative stress and increased atherogenicity
Preprint2023

Article2021
In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life
Article2021

Preprint2021
In (deficit) schizophrenia, a general cognitive decline (G-CoDe) partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life
Preprint2021